Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
J Alzheimers Dis Rep ; 5(1): 161-169, 2021 Mar 08.
Artigo em Inglês | MEDLINE | ID: mdl-33981953

RESUMO

BACKGROUND: There is a need for new practical tools to assess the cognitive impairment of small vessel disease (SVD) patients in the clinic. OBJECTIVE: This study aimed to examine cognitive functioning by administering the Virtual Supermarket (VST) in patients with SVD with cognitive impairment (SVD-CI, N = 32), cognitively normal SVD (SVD-CN, N = 37), and age-and education-matched healthy controls (HC, N = 30). METHODS: The tablet-based VST application and comprehensive traditional pencil-and-paper neuropsychological tests assessing memory, attention, executive function, visuospatial function, and language were administered to all participants. RESULTS: A moderate correlation was found between the "Duration" and "Correct Quantities" variables of VST and visuospatial function and general cognitive status composite Z scores across SVD-CI patients. "Duration" and "Correct Money" variables were moderately related to memory, executive functions, and visuospatial function composite Z scores across SVD-CN patients. A combination of all VST variables discriminated SVD-CI and HC with a correct classification rate of 81%, a sensitivity of 78%, and a specificity of 84%. CONCLUSION: This study is the first to evaluate cognitive functions employing the VST in SVD with and without cognitive impairment. It provides encouraging preliminary findings of the utility of the VST as a screening tool in the assessment of cognitive impairment and the differentiation of SVD patients from HC. In the future, validation studies of the VST with larger samples are needed.

2.
Artigo em Inglês | MEDLINE | ID: mdl-31482749

RESUMO

The purpose of this study was to investigate cognitive functioning by administering the Virtual Supermarket (VSM) test in patients with amnestic mild cognitive impairment (aMCI, N = 37) and age and education-matched healthy controls (HCs, N = 52). An extensive neuropsychological test battery and the VSM were administered to all participants. The aMCI group exhibited lower performance and required more time to complete the VSM compared to HCs. Also, aMCI-Multiple Domain (aMCI-MD) patients performed worse in the "Correct Types", "Correct Quantities", "Bought Unlisted", "Correct Money" variables compared to HCs. Moreover, aMCI-SD patients displayed lower performance in "Bought Unlisted" and "Correct Money" variables compared to HCs. The VSM variables correlated with established neuropsychological test scores. The VSM test was found to discriminate between aMCI and HCs with a correct classification rate (CCR) of 81%. This is a preliminary study showing that the VSM is a valid, brief and user-friendly test. .


Assuntos
Envelhecimento , Amnésia/diagnóstico , Disfunção Cognitiva/diagnóstico , Testes Neuropsicológicos/normas , Desempenho Psicomotor , Idoso , Envelhecimento/fisiologia , Comportamento do Consumidor , Diagnóstico por Computador , Feminino , Humanos , Masculino , Desempenho Psicomotor/fisiologia , Turquia , Realidade Virtual
3.
BMC Neurol ; 17(1): 208, 2017 Dec 06.
Artigo em Inglês | MEDLINE | ID: mdl-29207954

RESUMO

BACKGROUND: Cognitive impairment may be seen in as many as 43-70% of patients with multiple sclerosis (MS) and may be observed in all MS subtypes. The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS) battery may be used to evaluate cognition status. The purpose of the current study is to validate the BICAMS battery in Turkish. METHODS: Patients with MS attending our clinic between September 2014 and April 2015 were invited to participate. Healthy control participants were matched in terms of age, gender and years of education. RESULTS: One hundred seventy-three MS patients and 153 healthy control participants were enrolled in the study. MS patients performed significantly worse in all trials than the members of the healthy control group. In addition, cognitive dysfunction was identified in 78 of the 173 (45.1%) patients. In the MS with cognitive impairment group, 64 out of 151 (42.4%) subjects were RRMS patients, 12 out of 18 (66.7%) were secondary progressive MS patients, and 2 out of 4 (50%) were primer progressive MS patients. CONCLUSIONS: The BICAMS has been proposed for assessing cognitive impairment in MS patients. This study shows that the battery is suitable for use in Turkey.


Assuntos
Disfunção Cognitiva/diagnóstico , Esclerose Múltipla/complicações , Testes Neuropsicológicos , Adulto , Estudos de Casos e Controles , Feminino , Humanos , Masculino , Tradução , Turquia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA